Post-ERCP Pancreatitis Prevention in 2026: Rectal NSAIDs, Pancreatic Stents, and Practical Risk Reduction

Key Takeaways

  • Clinical Bottom Line
  • PEP prevention is a bundle, not a single trick
  • What the ASGE guideline still tells us
  • The 2024 trial changed how to talk about indomethacin alone

Clinical Bottom Line

Prevention step 2026 practical answer
Rectal NSAIDs Give rectal indomethacin 100 mg to most adults undergoing ERCP unless contraindications such as recent peptic ulcer disease or significant renal insufficiency are present.
Cannulation strategy Wire-guided cannulation is preferred over contrast-guided cannulation to reduce PEP risk.
High-risk pancreatic duct access Do not rely on NSAIDs alone when the pancreatic duct has been repeatedly or deeply accessed. Prophylactic pancreatic stenting still matters.
Hydration Aggressive lactated Ringer’s hydration remains reasonable in selected patients if heart failure, renal insufficiency, or advanced liver disease are not limiting factors.
Best mental model PEP prevention is a bundled strategy, not a single suppository.
Summary figure showing the layered prevention strategy for post-ERCP pancreatitis, including rectal NSAIDs, wire-guided cannulation, pancreatic stents in high-risk duct access, and selective lactated Ringer's hydration.
Figure. The lowest-risk ERCP is usually the one where pharmacologic, technical, and post-procedure prevention are all planned before the first cannulation attempt.

PEP prevention is a bundle, not a single trick

Rectal indomethacin remains a core part of prevention, but current practice is broader than a single-drug strategy. Post-ERCP pancreatitis prevention works best when the endoscopist treats it as a layered protocol that starts before cannulation, continues during the procedure, and does not ignore post-procedure physiology.

Busy doctors do not need another dramatic reminder that PEP is serious. They need a practical stack they can apply consistently.

What the ASGE guideline still tells us

The 2023 ASGE guideline remains the main U.S. procedural framework.

  • Use preprocedural rectal NSAIDs for unselected ERCP patients and for high-risk patients, with indomethacin 100 mg as the standard adult dose.
  • Prefer wire-guided cannulation over contrast-guided cannulation.
  • Place a prophylactic pancreatic stent in high-risk patients when the pancreatic duct has been repeatedly or deeply accessed, and consider it more broadly in high-risk patients when duct access is easy.
  • Use aggressive lactated Ringer’s hydration selectively when cardiorenal or hepatic limitations do not make that unsafe.

That structure matters because it prevents the common mistake of treating NSAIDs as a reason to relax on technique.

44% preview unlocked

Unlock the rest of this physician update

Enter your email to keep reading "Post-ERCP Pancreatitis Prevention in 2026: Rectal NSAIDs, Pancreatic Stents, and Practical Risk Reduction" and get practical GI endoscopy updates from GastroScholar.

  • Immediate access to the rest of this article
  • Practical endoscopy notes for busy doctors
  • One unlock covers the rest of the gated pilot posts on this browser

Scroll to Top